$ANIK
Anika Therapeutics, Inc. Stock $anik

$anik Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000117184324002682 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$41.92M	$40.52M	$42.97M
YoY Change	-5.37%	6.85%	8.45%
Cost Of Revenue	$14.56M	$15.90M	$16.64M
YoY Change	-5.05%	5.4%	7.43%
Gross Profit	$27.37M	$24.63M	$26.33M
YoY Change	-5.55%	7.81%	9.11%
Gross Profit Margin	65.28%	60.78%	61.27%
Selling, General & Admin	$19.81M	$21.53M	$20.34M
YoY Change	-16.39%	-6.06%	-11.77%
% of Gross Profit	72.38%	87.41%	77.23%
Research & Development	$7.398M	$8.164M	$7.585M
YoY Change	-17.01%	-2.81%	-2.12%
% of Gross Profit	27.03%	33.15%	28.81%
Depreciation & Amortization	$2.058M	$2.063M	$3.567M
YoY Change	-42.03%	-41.9%	-2.7%
% of Gross Profit	7.52%	8.38%	13.55%
Operating Expenses	$27.20M	$29.69M	$27.92M
YoY Change	-16.56%	-5.19%	-9.34%
Operating Profit	$161.0K	-$5.063M	-$1.591M
YoY Change	-104.43%	-40.24%	-76.14%
Interest Expense	$595.0K	$592.0K	$577.0K
YoY Change	6.06%	9.83%	109.06%
% of Operating Profit	369.57%
Other Income/Expense, Net
YoY Change
Pretax Income	$756.0K	-$4.471M	-$63.20M
YoY Change	-124.63%	-62.79%	888.95%
Income Tax	$800.0K	$43.00K	-$204.0K
% Of Pretax Income	105.82%
Net Earnings	-$88.00K	-$4.514M	-$63.00M
YoY Change	-96.79%	-56.39%	1183.62%
Net Earnings / Revenue	-0.21%	-11.14%	-146.61%
Basic Earnings Per Share	-$0.01	-$0.31
Diluted Earnings Per Share	-$0.01	-$0.31	-$4.30
COMMON SHARES
Basic Shares Outstanding	14.83M	14.85M	14.64M
Diluted Shares Outstanding	14.84M	14.70M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.82M	$68.63M	$72.87M
YoY Change	-3.46%	-13.93%	-15.59%
Cash & Equivalents	$62.82M	$68.63M	$72.87M
Short-Term Investments
Other Short-Term Assets	$6.941M	$8.848M	$8.095M
YoY Change	-10.89%	2.34%	-8.3%
Inventory	$51.46M	$49.41M	$46.39M
Prepaid Expenses
Receivables	$33.77M	$32.08M	$35.96M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$155.0M	$159.0M	$163.3M
YoY Change	1.84%	-0.85%	-3.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.69M	$46.06M	$74.97M
YoY Change	-0.63%	-41.68%	55.27%
Goodwill	$7.350M	$7.403M	$7.571M
YoY Change	-1.57%		3.16%
Intangibles	$3.969M	$4.297M	$4.626M
YoY Change	-94.39%		-93.8%
Long-Term Investments
YoY Change
Other Assets	$19.52M	$17.57M	$20.16M
YoY Change	0.69%	-10.58%	17.09%
Total Long-Term Assets	$107.7M	$104.8M	$107.3M
YoY Change	-39.07%	-41.38%	-40.24%
TOTAL ASSETS
Total Short-Term Assets	$155.0M	$159.0M	$163.3M
Total Long-Term Assets	$107.7M	$104.8M	$107.3M
Total Assets	$262.7M	$263.7M	$270.6M
YoY Change	-20.14%	-22.22%	-22.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.994M	$10.02M	$9.860M
YoY Change	25.81%	12.0%	8.66%
Accrued Expenses	$16.05M	$16.95M	$19.96M
YoY Change	10.07%	-10.12%	5.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.12M	$28.46M	$31.06M
YoY Change	11.36%	-0.81%	11.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$407.0K	$404.0K	$27.31M
YoY Change	1.5%	-98.59%	6761.31%
Total Long-Term Liabilities	$407.0K	$404.0K	$27.31M
YoY Change	1.5%	-98.59%	6761.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.12M	$28.46M	$31.06M
Total Long-Term Liabilities	$407.0K	$404.0K	$27.31M
Total Liabilities	$26.53M	$28.86M	$58.37M
YoY Change	11.2%	-53.06%	106.16%
SHAREHOLDERS EQUITY
Retained Earnings	$123.5M	$123.5M	$128.1M
YoY Change	-37.53%		-39.23%
Common Stock	$93.30M	$91.31M	$90.16M
YoY Change	13.04%		10.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$210.3M	$208.5M	$212.3M
YoY Change
Total Liabilities & Shareholders Equity	$262.7M	$263.7M	$270.6M
YoY Change	-20.14%	-22.22%	-22.48%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$88.00K	-$4.514M	-$63.00M
YoY Change	-96.79%	-56.39%	1183.62%
Depreciation, Depletion And Amortization	$2.058M	$2.063M	$3.567M
YoY Change	-42.03%	-41.9%	-2.7%
Cash From Operating Activities	-$1.069M	-$126.0K	$3.642M
YoY Change	-87.11%	-96.52%	657.17%
INVESTING ACTIVITIES
Capital Expenditures	$3.403M	$1.808M	$1.837M
YoY Change	133.56%	30.17%	-27.36%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$3.403M	-$1.808M	-$1.837M
YoY Change	133.56%	30.17%	-27.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.111M	-$2.273M	346.0K
YoY Change	-77.52%	40.92%	-48.13%
NET CHANGE
Cash From Operating Activities	-1.069M	-$126.0K	3.642M
Cash From Investing Activities	-3.403M	-$1.808M	-1.837M
Cash From Financing Activities	-1.111M	-$2.273M	346.0K
Net Change In Cash	-5.583M	-$4.238M	2.151M
YoY Change	-62.0%	-35.98%	-255.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.069M	-$126.0K	$3.642M
Capital Expenditures	$3.403M	$1.808M	$1.837M
Free Cash Flow	-$4.472M	-$1.934M	$1.805M
YoY Change	-54.13%	-61.37%	-188.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000898437
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68629000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72867000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	32077000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	35961000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	49408000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	46386000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8848000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8095000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	158962000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	163309000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46057000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46198000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28181000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28767000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17571000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18672000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1273000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1489000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4297000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4626000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	7403000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7571000	usd
CY2024Q1	us-gaap	Assets Assets	263744000	usd
CY2023Q4	us-gaap	Assets Assets	270632000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10022000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9860000	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18438000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	21199000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	28460000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31059000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	404000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	404000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26344000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26904000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14848000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14660000
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	148000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	147000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	91165000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90009000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6315000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5943000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	123538000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	128052000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	208536000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	212265000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263744000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270632000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	24628000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	22843000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8164000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8400000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21527000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26996000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	29691000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	35396000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5063000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12553000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	592000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	539000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4471000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12014000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1664000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4514000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10350000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14698000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14653000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14698000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14653000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4514000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10350000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-372000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	272000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4886000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10078000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	212265000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23000	usd
CY2024Q1	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	3430000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2296000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4514000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-372000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	208536000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	285563000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	3717000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1621000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10350000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	272000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	277588000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4514000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10350000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1734000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1605000	usd
CY2024Q1	anik	Amortization Of Acquisition Related Intangible Assets AmortizationOfAcquisitionRelatedIntangibleAssets	329000	usd
CY2023Q1	anik	Amortization Of Acquisition Related Intangible Assets AmortizationOfAcquisitionRelatedIntangibleAssets	1946000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	565000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	542000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3590000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3717000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	193000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2373000	usd
CY2024Q1	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	93000	usd
CY2023Q1	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	24000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	2063000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	629000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3624000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4057000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4090000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3063000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	548000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	401000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-713000	usd
CY2024Q1	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-546000	usd
CY2023Q1	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-523000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3110000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	665000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	90000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	681000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-126000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3618000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1808000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1389000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1808000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1389000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2296000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1620000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2273000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1613000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-31000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4238000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6590000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72867000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86327000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68629000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79737000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	622000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	729000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody><tr> <td style="vertical-align: top; width: 3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b></p> </td> <td style="vertical-align: top; width: 97%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Nature of Business</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 33pt;">Anika Therapeutics, Inc. (the “Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 33pt;">In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into joint preservation and restoration, added higher-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 33pt;">The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p>
CY2024Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	33735000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	37580000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1658000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1619000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32077000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35961000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1619000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1608000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	185000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	102000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	92000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	78000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	45000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	106000	usd
CY2024Q1	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-9000	usd
CY2023Q1	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	11000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1658000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1537000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16264000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	15507000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17264000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17002000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	33048000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	32084000	usd
CY2024Q1	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	66576000	usd
CY2023Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	64593000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	49408000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	46386000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	17168000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	18207000	usd
CY2024Q1	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	66576000	usd
CY2023Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	64593000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	13600000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	11700000	usd
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	49945000	usd
CY2024Q1	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	3218000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42430000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4297000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4626000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P13Y
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1900000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1008000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	274000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	160000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	160000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	160000	usd
CY2024Q1	anik	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	886000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2648000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7571000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-168000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	7403000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8595000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11828000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3434000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3240000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2129000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2133000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	1904000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	1904000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1490000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1240000	usd
CY2024Q1	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	249000	usd
CY2023Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	460000	usd
CY2024Q1	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	160000	usd
CY2023Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	0	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	477000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	394000	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18438000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	21199000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40523000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37924000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40523000	usd
CY2024Q1	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37924000	usd
CY2023Q1	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3590000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3717000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1812729
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.42
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	127000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	426925
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.93
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1089
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	21.77
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26128
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	29.99
CY2024Q1	anik	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue	22000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2212437
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	32.41
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	316000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1305902
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	35.24
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	38000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2212437
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.41
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	316000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	426925
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	anik	Sharebased Compensation Arrangement By Share Based Payment Award Fair Value Per Option SharebasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption	0.1048
CY2023Q1	anik	Sharebased Compensation Arrangement By Share Based Payment Award Fair Value Per Option SharebasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption	0.1171
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.139	pure

Files In Submission

Name	View Source	Status
0001171843-24-002682-index-headers.html	Edgar Link	pending
0001171843-24-002682-index.html	Edgar Link	pending
0001171843-24-002682.txt	Edgar Link	pending
0001171843-24-002682-xbrl.zip	Edgar Link	pending
anik-20240331.xsd	Edgar Link	pending
anik20240331c_10q.htm	Edgar Link	pending
ex_665260.htm	Edgar Link	pending
ex_665261.htm	Edgar Link	pending
ex_665262.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
anik-20240331_def.xml	Edgar Link	unprocessable
anik-20240331_lab.xml	Edgar Link	unprocessable
anik-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
anik20240331c_10q_htm.xml	Edgar Link	completed
anik-20240331_cal.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIK
Anika Therapeutics, Inc. Stock $anik

2024 Q2 Form 10-Q Financial Statement

#000117184324002682 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK Anika Therapeutics, Inc. Stock $anik

2024 Q2 Form 10-Q Financial Statement

#000117184324002682 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK
Anika Therapeutics, Inc. Stock $anik